HRGN Harvard Apparatus Regenerative Technology, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Harvard Apparatus Regenerative Technology, Inc. reported revenue of $414K (up 30.6% from a year earlier), net income of −$1.70M and diluted EPS of n/a; over the last four quarters revenue was $982K and net income −$6.68M; for the fiscal year ended December 2025 revenue was $704K, up 63.7% on the year before.
HRGN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $704K, gross profit n/a, operating income −$6.92M, net income −$6.87M (margin -975.7%), EPS n/a
- Fiscal year ended Dec 2024: revenue $430K, gross profit n/a, operating income −$7.73M, net income −$7.73M (margin -1798.1%), EPS n/a
- Fiscal year ended Dec 2023: revenue $103K, gross profit n/a, operating income −$8.99M, net income −$9.02M (margin -8759.2%), EPS −$0.67
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$6.15M, net income −$6.07M (margin n/a), EPS −$0.55
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$8.64M, net income −$7.98M (margin n/a), EPS −$0.79
HRGN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $414K (up 30.6% year over year), net income −$1.70M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $226K (up 402.2% year over year), net income −$1.60M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $219K (down 15.1% year over year), net income −$1.69M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $123K (up 108.5% year over year), net income −$1.70M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $317K (up 466.1% year over year), net income −$1.82M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $45.0K (down 21.1% year over year), net income −$1.66M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $258K, net income −$1.34M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $59.0K (up 47.5% year over year), net income −$1.86M, EPS −$0.12
- Quarter ended Jun 30, 2024: revenue $56.0K, net income −$2.50M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue $57.0K, net income −$2.03M, EPS −$0.15
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.90M, EPS −$0.12
- Quarter ended Sep 30, 2023: revenue $40.0K, net income −$1.62M, EPS −$0.12
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.61M, EPS −$0.19
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.89M, EPS −$0.24
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.50M, EPS −$0.13
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.06M, EPS −$0.10
- Quarter ended Jun 30, 2022: revenue $0, net income −$1.35M, EPS −$0.12
- Quarter ended Mar 31, 2022: revenue $0, net income −$2.18M, EPS −$0.20
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$5.87M, EPS −$0.58
- Quarter ended Sep 30, 2021: revenue $0, net income −$849K, EPS −$0.08
HRGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$3.83M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.85M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$6.94M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.11M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$2.63M, share buybacks $0
HRGN balance sheet
- Jun 30, 2026: cash $351K, total assets $1.69M, total liabilities $3.06M, shareholders' equity −$1.38M
- Mar 31, 2026: cash $419K, total assets $1.80M, total liabilities $1.71M, shareholders' equity $92.0K
- Dec 31, 2025: cash $1.35M, total assets $2.68M, total liabilities $1.62M, shareholders' equity $1.06M
- Sep 30, 2025: cash $1.32M, total assets $2.55M, total liabilities $992K, shareholders' equity $1.55M
- Jun 30, 2025: cash $786K, total assets $2.14M, total liabilities $1.38M, shareholders' equity $761K
- Mar 31, 2025: cash $1.73M, total assets $3.42M, total liabilities $1.37M, shareholders' equity $2.05M
- Dec 31, 2024: cash $2.49M, total assets $4.44M, total liabilities $1.22M, shareholders' equity $3.22M
- Sep 30, 2024: cash $3.59M, total assets $5.31M, total liabilities $1.47M, shareholders' equity $3.84M
What is HRGN's revenue?
Harvard Apparatus Regenerative Technology, Inc. reported $982K of revenue over its last four quarters, through June 30, 2026.
Is HRGN profitable?
No. Harvard Apparatus Regenerative Technology, Inc. lost $6.68M over the last four quarters.